26 May 2026

​

genedrive plc

("genedrive" or the "Company")

Board changes

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr David Nugent has joined the Board as a Non-Executive Director with immediate effect. David has been a shareholder in the Company for several years and more recently was a key cornerstone investor in the successful equity financing announced on 13 February 2026. He owns over 25% of the Company's issued share capital and is the Company's largest shareholder. David has volunteered not to be paid a fee for acting as a Non-Executive Director until the Company becomes EBITDA positive.

Further, Dr. Ian Gilham, who has been a Director of the Company since 2014, including acting as Chairman since 2015, has informed the Board that he anticipates stepping down as Chairman and a Director of genedrive by the end of June 2026. In addition, Chris Yates, who has been a Non-Executive Director of the Company since 2018 has informed the Board that he intends to step down as a Director to focus on his other professional commitments.  Chris has agreed to assist the Board during the process to appoint new Non-Executive Board members prior to stepping down sometime over the coming weeks.

The Board is commencing the process to recruit a new independent Non-Executive Chairman as well as two other independent Non-Executive Directors and further announcements will be made in due course. 

Dr. Ian Gilham, Chairman of genedrive plc, said: "On behalf of my fellow Directors I am pleased to welcome David onto the Board today. His support for the Company has been critical to funding our continued growth strategy and we look forward to working closely with him as we execute against our plans to increase the sales and adoption of our two pharmacogenetic tests. Having served as Director of the Company since 2014 it is appropriate that we start the process to find a new Non-Executive Chairman and the Company will update shareholders on this process in due course."

David Nugent, Non-Executive Director of genedrive plc, said on his appointment: "I would like to thank Ian and Chris for their commitment to genedrive and recognise their significant contribution over many years. I look forward to continuing to work with them as we appoint a Chair and two independent Non-Executive Directors.

"genedrive is in its strongest position for many years, with two point-of-care pharmacogenetic tests now on the market which offer highly promising commercial opportunities. I am excited to be joining the Board and working with Gino and Russ as the Company drives adoption and executes its commercial strategy in the UK and internationally."

Additional Information on the Board Appointment

The following additional information is provided with regards to the appointment of David Grant Nugent, aged 57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

David Nugent was a director of Howard Nugent Limited which was wound up under the provisions of the Insolvency Act 1986 in March 2011.

David Nugent and his connected parties hold 401,500,000 ordinary shares in the Company as detailed in the TR1 announcement issued on 6 May 2026.

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03 

About genedrive plc (http://www.genedrive.com).

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.